Your Messages Inbox
Your Article Summary
See Latest ArticlesAnti-malignancy agent / anti-VEGF humanised monoclonal antibody, Avastin; Application for Approval of Additional Indication of NSCLC
Chugai Pharmaceutical Co., 01/13/09
Chugai Pharmaceutical Co., Ltd. announced that the company filed an application with the Japanese Ministry of Health, Labour and Welfare for the approval of an additional indication of non-small cell lung cancer (NSCLC) for the anti-malignancy agent / anti-VEGF1 humanised monoclonal antibody, "AVASTIN I.V. Infusion 100mg/4mL and 400mg/16mL". Avastin; has been approved in Japan for the treatment of unresectable advanced or recurrent colorectal cancer. Avastin; is a novel drug that inhibits the growth of a network of blood vessels that supply nutrients and oxygen to cancerous tissue.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
Novartis, 12/04/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Bayer's Betaferon approved in China for Treatment of Multiple Sclerosis
BayNews International, 12/02/09
Article Search
Sponsor